Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Core Insights - Milestone Pharmaceuticals Inc. is set to present data on the efficacy, safety, and tolerability of self-administered etripamil for paroxysmal supraventricular tachycardia at the American Heart Association Scientific Sessions 2025 [1][2] - The presentation will be led by Dr. James Ip and is scheduled for November 10, 2025 [2] - The company has submitted a New Drug Application (NDA) to the FDA for etripamil targeting abnormal heart rhythms [3] Company Overview - Milestone Pharmaceuticals Inc. focuses on developing and commercializing innovative cardiovascular medicines [3] - The company aims to benefit individuals with specific heart conditions through its product offerings [3]